Search Results
Aug 24, 2026, 19:22 ET PEI-Genesis ने भारत की नई दिल्ली में आयोजित AEDEX में प्रदर्शनी लगाई
करने के लिए डिज़ाइन किए गए उच्च-कार्यक्षमता और मजबूत इंटरकनेक्ट समाधानों का एक व्यापक पोर्टफ़ोलियो प्रदर्शित किया जाएगा। प्रमुख सप्लाइयरों में Amphenol, ITT Cannon, Cinch Connectivity Solutions, Positronic, Eaton Souriau और अन्य शामिल हैं।
More news about: PEI-Genesis
Aug 24, 2026, 01:30 ET PEI-Genesis Exhibits at AEDEX in New Delhi, India
interconnect solutions engineered to meet the demanding requirements of military, aerospace and defence applications. Featured suppliers include Amphenol, ITT Cannon, Cinch Connectivity Solutions, Positronic, Eaton Souriau, and others.
More news about: PEI-Genesis
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. Overall survival is
More news about: Karyopharm Therapeutics Inc.
Aug 12, 2026, 07:00 ET Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
supporting a blood-based patient-selection test.Results in the overall intent-to-treat (ITT) populationThe prespecified primary endpoint of PFS in the ITT population was not met. Median PFS was 9.2 months in the Sirexatamab Arm versus 8.3 months in the Control
More news about: Cypherpunk Technologies Inc.
Aug 07, 2026, 11:20 ET /C O R R E C T I O N -- Fundstrat Capital/
SummaryAdditions: CRDO, DKS, FSLR, MOD, NBIX, NTRA, RMBS, TTMI, ZETA, ZMDeletions: ARRY, AWI, CARR, DCI, H, IBP, ITT, UHSThe rebalance reflects updated positioning across Fundstrat Capital's proprietary Granny Shots investment framework, which identifies small-
More news about: Fundstrat Capital
Aug 05, 2026, 06:59 ET Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
scalp hair coverage) response at Week 36 in the mITT analysis and 30.3% of patients achieved a SALT-20 response at Week 36 in the intent-to-treat ("ITT") analysis of all enrolled patients. In Part B, bempikibart was generally well-tolerated, consistent with prior studies, with no new safety signals,
More news about: Q32 Bio
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. Overall survival is
More news about: Karyopharm Therapeutics Inc.
Jul 17, 2026, 08:00 ET Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
investigator and subject assessments using the 4-point Facial Wrinkle Scale (FWS) (0=none, 1=mild, 2=moderate, 3=severe) at Day 7. Efficacy was assessed in the ITT population with baseline FLO-11 Total Transformed Score of ≤50. Secondary efficacy endpoints were measured by FLSQ, a scale developed by Allergan Aesthetics,
More news about: AbbVie
Jul 13, 2026, 06:59 ET Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
patients in the intent-to-treat (ITT) analysis achieved a SALT-20 response. Achievement of a SALT-20 response was observed in patients with both severe and very severe disease.44.0% (11/25) of patients in the mITT analysis and 33.3% (11/33) of patients in the ITT analysis achieved SALT30
More news about: Q32 Bio
Jul 10, 2026, 06:59 ET Data Center Pumps Market worth $7.35 billion by 2032 - Exclusive Report by MarketsandMarkets™
manufacturing footprint, installed base, and strong relationships with hyperscale, colocation, and enterprise data center operators.Sulzer, EBARA, ITT, Pentair, SPP Pumps, and several regional pump manufacturers have strengthened their presence in the data center pump market by offering specialized
More news about: MarketsandMarkets
Jun 23, 2026, 08:00 ET Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
severity at maximum frown based on both investigator and subject assessments using the Facial Wrinkle Scale (FWS) at Day 7. Efficacy was assessed in the ITT population. The composite responder rates at Day 7 were 60.0% and 65.7% (M2-500: n=289/482; M21-508: n=149/227; p<0.0001). Secondary efficacy
More news about: AbbVie
Jun 23, 2026, 05:00 ET AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
(SVR12) in the intent-to-treat population (ITT). The study met its primary endpoint, with 96.2% of patients in the ITT population achieving SVR12 (p<0.0001). The key secondary endpoint was also met with 100% of patients in the modified ITT-Virologic Failure population achieving SVR12
More news about: AbbVie
Jun 16, 2026, 14:40 ET Reworld® Appoints Brendan Ferretti as EVP, Business Development and M&A
and legal and compliance functions. Additionally, he held global finance and operating leadership roles at publicly listed organizations, including ITT and General Electric. Ferretti earned a Bachelor of Arts in Economics from Hamilton College and is a First Movers Fellow at the Aspen Institute.This
More news about: Reworld Holding Corporation
Jun 11, 2026, 00:54 ET Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
and tolerability. CBL-514 has demonstrated superior, precise efficacy and solid safety profiles across different indications in both Intent-to-Treat (ITT) and Full Analysis Set (FAS) populations, reaching high statistical significance.For more information about CBL-514, please visit :
More news about: Caliway Biopharmaceuticals
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
months:34% reduction in the risk of death - ivonescimab plus chemotherapy significantly prolonged OSIn the intent-to-treat (ITT) population, ivonescimab plus chemotherapy reduced the risk of death by 34% versus tislelizumab plus chemotherapy (HR=0.66 [95% CI: 0.50–0.87], P=0.0017(＜0.0049).
More news about: Akeso, Inc.
May 26, 2026, 16:15 ET McCormick Appoints Cindy Hoots to Board of Directors
AstraZeneca, Ms. Hoots was Global Vice President, Technology at Unilever, and has held several IT and business leadership roles at BAT p.l.c., SABMiller, ITT Inc. and Mars Incorporated. Ms. Hoots is a member of the Board of Directors of Zoom Communications, Inc., advises startups, and serves on the Digital
More news about: McCormick & Company, Incorporated
May 22, 2026, 08:00 ET AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
(SVR12) in the intent-to-treat population (ITT). The study met its primary endpoint, with 96.2% of patients in the ITT population achieving SVR12 (p<0.0001). The key secondary endpoint was also met with 100% of patients in the modified ITT-Virologic Failure population achieving SVR12
More news about: AbbVie
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
surgery. At two and/or four weeks after surgery, researchers performed intraperitoneal glucose tolerance testing (IPGTT), insulin tolerance testing (ITT), glucose-stimulated insulin secretion (GSIS), calculated HOMA-IR and assessed glucagon secretion. Mice were then euthanized for pancreatic histology,
More news about: Genprex, Inc.
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. The key secondary endpoint of overall survival will be evaluated in the ITT population. The mITT population is expected to
More news about: Karyopharm Therapeutics Inc.
May 05, 2026, 10:00 ET Synagro to Highlight Products and Services at WEF Residuals & Biosolids and Innovations in Treatment Technology Conference
announce its participation in the Water Environment Federation (WEF) Residuals & Biosolids and Innovations in Treatment Technology Conference (RB/ITT26) in Kansas City, Missouri, May 11-14, 2026, at the Kansas City Convention Center.
More news about: Synagro Technologies, Inc.
Apr 30, 2026, 09:07 ET JASMINE Trial Demonstrates Prolacta's Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan's Renowned Low NEC Rate
(EHMD) demonstrated significantly better weight gain velocity (13.44 vs. 11.96 g/kg/day, p = 0.006), compared to infants fed the Standard Diet (in the ITT set).1 In the per protocol set (PPS), the EHMD group demonstrated an even greater difference in weight gain compared to the Standard
More news about: Prolacta Bioscience
Apr 28, 2026, 09:15 ET Busch Gardens Salutes Veterans and their Families with Free Park Admission for Military Appreciation Month
and up to three dependents per year to Busch Gardens. Additional discounts and offers are available for active military and veterans through MWR and ITT offices on U.S. military bases and online at
More news about: United Parks and Resorts Inc.
Apr 28, 2026, 09:00 ET SeaWorld Salutes Veterans and their Families with Free Park Admission for Military Appreciation Month
themselves and up to three dependents per year to SeaWorld. Additional discounts and offers are available for active military and veterans through MWR and ITT offices on U.S. military bases and online at
More news about: United Parks and Resorts Inc.
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
surgery. At two and/or four weeks after surgery, researchers performed intraperitoneal glucose tolerance testing (IPGTT), insulin tolerance testing (ITT), glucose-stimulated insulin secretion (GSIS), calculated HOMA-IR and assessed glucagon secretion. Mice were then euthanized for pancreatic histology,
More news about: Genprex, Inc.
Apr 28, 2026, 06:29 ET Zimmer Biomet Announces Chief Financial Officer Transition
Services; Vice President, Controller and Chief Accounting Officer; and Vice President of Financial Planning and Analysis. Stellato also spent eight years at ITT Corporation, where he held various roles of increasing responsibility in the finance organization. He spent his early career in public accounting with
More news about: Zimmer Biomet Holdings, Inc.